These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24964698)

  • 21. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
    Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
    J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk attitudes to treatment among patients with severe intermittent claudication.
    Letterstål A; Forsberg C; Olofsson P; Wahlberg E
    J Vasc Surg; 2008 May; 47(5):988-94. PubMed ID: 18455642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life of young adults and adolescents with chronic kidney disease.
    Tong A; Wong G; McTaggart S; Henning P; Mackie F; Carroll RP; Howard K; Craig JC
    J Pediatr; 2013 Oct; 163(4):1179-85.e5. PubMed ID: 23800404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index.
    Dan AA; Kallman JB; Srivastava R; Younoszai Z; Kim A; Younossi ZM
    Liver Transpl; 2008 Mar; 14(3):321-6. PubMed ID: 18306356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis.
    Lillegraven S; Kristiansen IS; Kvien TK
    Ann Rheum Dis; 2010 Oct; 69(10):1762-7. PubMed ID: 20448285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of social care for adults: developing a preference-weighted measure.
    Netten A; Burge P; Malley J; Potoglou D; Towers AM; Brazier J; Flynn T; Forder J; Wall B
    Health Technol Assess; 2012; 16(16):1-166. PubMed ID: 22459668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new explanation for the difference between time trade-off utilities and standard gamble utilities.
    Bleichrodt H
    Health Econ; 2002 Jul; 11(5):447-56. PubMed ID: 12112493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Handling time in economic evaluation studies.
    Permsuwan U; Guntawongwan K; Buddhawongsa P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S50-8. PubMed ID: 24964699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The burden of depressive disorders in Germany - results from the European Study of the Epidemiology of Mental Disorders (ESEMeD)].
    Günther OH; Friemel S; Bernert S; Matschinger H; Angermeyer MC; König HH
    Psychiatr Prax; 2007 Sep; 34(6):292-301. PubMed ID: 17806016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?
    Boye KS; Matza LS; Feeny DH; Johnston JA; Bowman L; Jordan JB
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):437-50. PubMed ID: 24832003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years.
    Franic DM; Bothe AK; Bramlett RE
    J Fluency Disord; 2012 Dec; 37(4):300-13. PubMed ID: 23218213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?
    Flood C
    J Ment Health Policy Econ; 2010 Jun; 13(2):65-72. PubMed ID: 20919593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The responsiveness of quality of life utilities to change in depression: a comparison of instruments (SF-6D, EQ-5D, and DFD).
    Gerhards SA; Huibers MJ; Theunissen KA; de Graaf LE; Widdershoven GA; Evers SM
    Value Health; 2011; 14(5):732-9. PubMed ID: 21839412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL).
    Williams K; Gibson A; McNamara L; Jones T; Lloyd AJ
    J Med Econ; 2020 Oct; 23(10):1142-1150. PubMed ID: 32644862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding quality-adjusted life years and their application to pharmacoeconomic research.
    Raisch DW
    Ann Pharmacother; 2000; 34(7-8):906-14. PubMed ID: 10928403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia.
    Palmer AJ; Campbell JA; de Graaff B; Devlin N; Ahmad H; Clarke PM; Chen M; Si L
    Health Econ; 2021 Aug; 30(8):1950-1977. PubMed ID: 34018630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review.
    Räsänen P; Roine E; Sintonen H; Semberg-Konttinen V; Ryynänen OP; Roine R
    Int J Technol Assess Health Care; 2006; 22(2):235-41. PubMed ID: 16571199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
    Nimdet K; Ngorsuraches S
    BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.